If you have been reading about chelation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
| Property | Value | Notes |
|---|---|---|
| Physical state | Blue-violet solid | Typically supplied as lyophilized powder |
| Storage temperature | −20 °C or below | Desiccated, protected from light |
| Working stability | Hours to days at 2–8 °C | Depends on concentration and buffer |
| Identity test | RP-HPLC with UV-Vis | Visible absorbance near 600–630 nm |
| Copper assay | ICP-MS or AAS | Metal content confirms stoichiometry |
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
=== Transgenic plant and animals === In recent years, expression vectors have been used to introduce specific genes into plants and animals to produce transgenic organisms, for example in agriculture it is used to produce transgenic plants. Expression vectors have been used to introduce a vitamin A precursor, beta-carotene, into rice plants. This product is called golden rice. This process has also been used to introduce a gene into plants that produces an insecticide, called Bacillus thuringiensis toxin or Bt toxin which reduces the need for farmers to apply insecticides since it is produced by the modified organism. In addition expression vectors are used to extend the ripeness of tomatoes by altering the plant so that it produces less of the chemical that causes the tomatoes to rot. There have been controversies over using expression vectors to modify crops due to the fact that there might be unknown health risks, possibilities of companies patenting certain genetically modified food crops, and ethical concerns. Nevertheless, this technique is still being used and heavily researched. Transgenic animals have also been produced to study animal biochemical processes and human diseases, or used to produce pharmaceuticals and other proteins. They may also be engineered to have advantageous or useful traits. Green fluorescent protein is sometimes used as tags which results in animal that can fluoresce, and this have been exploited commercially to produce the fluorescent GloFish.
== External links == glycosciences.de This site provides databases and bioinformatics tools for glycobiology and glycomics. GlycomeDB, A carbohydrate structure metadatabase GlycoBase A web HPLC/UPLC resource that contains elution positions expressed as glucose unit values. ProGlycAn A short introduction to glycan analysis and a nomenclature for N-Glycans Emanual Maverakis; et al. "Glycans in the immune system and The Altered Glycan Theory of Autoimmunity" (PDF). CD BioGlyco This site provides database and tools in the field of glycomics, from glycan release, separation, and purification, glycan derivatization to glycan characterization and quantification.
== Features == SENP1 (Sentrin-specific protease 1) is a human protease of 643 amino acids with a molecular weight of 73 kDa, EC number in humans 3.4.22.B70. It adopts a conformation that identifies it as a member of the superfamily of cysteine proteases, which contain a catalytic triad with three characterized amino acids: a cysteine at position 603, a histidine at position 533 and aspartic acid at position 550. The primary nucleophile is cysteine located at the N-terminal alpha helix of the protein core. The other two amino acids, aspartate and histidine, are located in the end of a beta sheet.
In addition, if the medicine has distributed fully at equilibrium in the body, which is called the volume of distribution at a stable state. In case the loading dose was administered after the CRI, the time period of which will keep the concentration at a stable state equals 3 time constants or 5 terminal half-lives of the specific medicine. The bolus dose can full with the volume of the medicine in an efficient and effective way so that the medicine can be cleared and delivered. This also can promote to achieve the stable state in a prompter approach. Administering a CRI has two important methods: targeting a specific infusion rate, and making the infusion rate constant.
RO5073012 is a selective low-efficacy partial agonist of the trace amine-associated receptor 1 (TAAR1) which has been used in scientific research. TAAR1 partial agonists like RO5073012 can have agonist- or antagonist-like effects at the TAAR1 depending on the context and level of TAAR1 signaling.
Sources: en.wikipedia.org
In the absence of an effective enantiomeric environment (precursor, chiral catalyst, or kinetic resolution), separation of a racemic mixture into its enantiomeric components is impossible, although certain racemic mixtures spontaneously crystallize in the form of a racemic conglomerate, in which crystals of the enantiomers are physically segregated and may be separated mechanically. However, most racemates form crystals containing both enantiomers in a 1:1 ratio. In his pioneering work, Louis Pasteur was able to isolate the isomers of sodium ammonium tartrate because the individual enantiomers crystallize separately from solution. To be sure, equal amounts of the enantiomorphic crystals are produced, but the two kinds of crystals can be separated with tweezers. This behavior is unusual. A less common method is by enantiomer self-disproportionation. The second strategy is asymmetric synthesis: the use of various techniques to prepare the desired compound in high enantiomeric excess. Techniques encompassed include the use of chiral starting materials (chiral pool synthesis), the use of chiral auxiliaries and chiral catalysts, and the application of asymmetric induction. The use of enzymes (biocatalysis) may also produce the desired compound. A third strategy is enantioconvergent synthesis, the synthesis of one enantiomer from a racemic precursor, utilizing both enantiomers. By making use of a chiral catalyst, both enantiomers of the reactant result in a single enantiomer of product.
In addition to the classical nuclear AR, bicalutamide has been assessed at the membrane androgen receptors (mARs) and found to act as a potent antagonist of ZIP9 (IC50 = 66.3 nM), whereas it does not appear to interact with GPRC6A. The affinity of bicalutamide for the AR is relatively low as it is approximately 30 to 100 times lower than that of DHT, which is 2.5- to 10-fold as potent as an AR agonist as testosterone in bioassays and is the main endogenous ligand of the receptor in the prostate gland. However, typical clinical dosages of bicalutamide result in circulating levels of the drug that are thousands of times higher than those of testosterone and DHT, allowing it to powerfully prevent them from binding to and activating the receptor. This is especially true in the case of surgical or medical castration, in which testosterone levels in the circulation are approximately 95% reduced and DHT levels in the prostate gland are about 50 to 60% reduced. In women, levels of testosterone are substantially lower (20- to 40-fold) than in men, so much smaller doses of bicalutamide (e.g., 25 mg/day in the hirsutism studies) are necessary. Blockade of the AR by bicalutamide in the pituitary gland and hypothalamus results in prevention of the negative feedback of androgens on the hypothalamic–pituitary–gonadal axis (HPG axis) in males and consequent disinhibition of pituitary luteinizing hormone (LH) secretion. This, in turn, results in an increase in circulating LH levels and activation of the gonadal production of testosterone and by extension production of estradiol.
==== Feud with outgoing Vice President Verónica Abad Rojas ==== Upon their inauguration in November 2023, both Noboa and Abad Rojas distanced themselves from each other, with Abad Rojas launching personal attacks against Noboa. She did not appear in the inaugural photo of the cabinet and subsequently was appointed ambassador to Israel. Shortly thereafter, she was ordered to move to Istanbul within three days. Abad Rojas called these decisions a "forced exile". In June 2024, Abad Rojas survived an impeachment attempt by the Noboa government due to legal issues. In November 2024, she was suspended from the vice presidency by the labor ministry for 150 days. Noboa named Secretary of National Planning Sariha Moya as acting vice president. Abad Rojas' suspension was lifted by a judge in December 2024, along with an order for the labor ministry to give her an apology for the suspension. According to Ecuador's electoral law, the president is required to take a leave of absence during the presidential campaign and appoint the elected vice-president to act as president temporarily. Noboa refused to appoint Abad Rojas as interim president during the election campaign. Instead, in January 2025, he appointed Cynthia Gellibert as vice president with temporary presidential responsibilities during the campaign. On 30 March 2025, Noboa caused controversy for ignoring the Constitutional Court and appointing Cynthia Gellibert by decree as vice president, suspending Abad Rojas once again.
UPMC has its roots in the 1893 establishment of Presbyterian Hospital, which serves as the medical center's flagship facility, and the 1886 founding of the Western Pennsylvania Medical College. Soon after its founding, the medical college became affiliated with the Western University of Pennsylvania in 1892, and in 1908, was fully integrated into the university which that same year was renamed to the University of Pittsburgh. Already having informal agreements for teaching and staffing privileges with a number of local hospitals, Pitt and its School of Medicine desired to establish an academic medical center, and by the mid-1920s had formed a plan with city hospitals to have them relocate to the Oakland neighborhood where the university had moved in 1909. The university provided Presbyterian Hospital on the North Side, with a tract of land on its campus to construct a new hospital which broke ground in 1930 and opened in 1938. By the end of the 1930s, the University of Pittsburgh had helped to form the "University Medical Center" including Falk Clinic, Children's, Eye and Ear, Libby Steele Magee, Presbyterian General, and Women's Hospital, as well as the planned Municipal Hospital. In 1949, a new agreement between the university and Presbyterian Hospital established a three-tiered mission of patient care, research, and education, and by 1951, the hospital name was changed to Presbyterian University Hospital to reflect its close ties with the University of Pittsburgh.
A daily 0.2 mg dose of naldemedine has been shown to significantly improve symptoms in patients with OIC. Opioid rotation is one method suggested to minimise the impact of constipation in long-term users. While all opioids cause constipation, there are some differences between drugs, with studies suggesting tramadol, tapentadol, methadone and fentanyl may cause relatively less constipation, while with codeine, morphine, oxycodone or hydromorphone constipation may be comparatively more severe.
Sources: en.wikipedia.org
== External links == "Moxetumomab Pasudotox-tdfk". National Cancer Institute. 24 October 2018. Archived from the original on 19 October 2021. Retrieved 11 October 2020. "Moxetumomab Pasudotox-tdfk". NCI Drug Dictionary. National Cancer Institute.
=== Organometallic clusters === Organometallic Fe–S clusters include the sulfido carbonyls with the formula Fe2S2(CO)6, H2Fe3S(CO)9, and Fe3S2(CO)9. Compounds are also known that incorporate cyclopentadienyl ligands, such as (C5H5)4Fe4S4.
"Novel Liquid Crystalline Compounds and Polymers,"J.S. Bradshaw, M.L. Lee, K.E. Markides, and B.A. Jones. US Patent Number 4,864,033. Filed: November 27, 1985. Issued: February 1989. "Multi-Element Selective Radio Frequency Plasma Detector for Capillary Gas Chromatography, F. Yang, P. Farnsworth, R. Skelton, K.E. Markides, and M.L. Lee. U.S. Patent Application Serial No. 24,095. Filed: March 12, 1987. Issued: January 25, 1989. "Oligoethylene Oxide Substituted Siloxane Compounds and Polymers," J.S. Bradshaw, M.L. Lee, K.E. Markides, Filed: December, 1987. "Chiral Polysiloxane Compounds and Polymers," J.S. Bradshaw, M.L. Lee, K.E. Markides, Filed: January, 1988. Issued: June 1990. "Chromatographic Arylcarboxamide Polysiloxanes," J.S. Bradshaw, M.L. Lee, K.E. Markides, Filed: June, 1988. Issued: March 1990. "Novel Chiral Copolymers with Oligosiloxane Spacers," J.S. Bradshaw, B.E. Rossiter, B.J. Tarbet, D.F. Johnson, M.L. Lee, K.E. Markides, File No. 9393 CIP. Filed: March 1992. “Encapsulated Nanoparticles for Drug Delivery”, G. Jacobson, R.N. Zare, K.E. Markides, R.R. Shinde and C.H. Contag, File No. 11/748,408, Filed: May 14, 2007.
An embalmer is someone who has been trained and qualified in the art and science of sanitization, presentation, and preservation of the human deceased. The term mortician is far more generic; it may refer to someone who is a funeral director, an embalmer, or just a person who prepares the deceased, with or without the formal qualification of an embalmer. Thus while all embalmers are morticians, many morticians are not embalmers and the terms are not intrinsically synonymous. Embalming training commonly involves formal study in anatomy, thanatology, chemistry, and specific embalming theory (to widely varied levels depending on the region of the world one lives in) combined with practical instruction in a mortuary with a resultant formal qualification granted after the passing of a final practical examination and acceptance into a recognized society of professional embalmers. The roles of a funeral director and embalmer are different, depending on local customs and the licensing body of the region in which they both operate. A funeral director arranges for the final disposition of the deceased, and may or may not prepare the deceased (by embalming, preparing for viewing or other legal requirements). Legal requirements over who can practice vary geographically. Some regions or countries do not have specific requirements, while others have clear prohibitions. In the United States, the title of an embalmer is largely based on the state in which they are licensed.
Sources: en.wikipedia.org
Dry powder is typically stored frozen at −20 °C or lower, protected from moisture and light. Short-term working amounts may be kept refrigerated. Avoiding repeated temperature changes helps preserve the material.
Reversed-phase HPLC with UV-visible detection is common because the copper complex absorbs visible light. Mass spectrometry provides molecular mass confirmation. Copper-specific methods such as ICP-MS quantify the metal content.
The blue color comes from copper-ligand interactions. Displacement of copper by chelators or changes in pH can shift or diminish the color. Such changes often indicate that the complex has been altered.
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.